From Surf Wiki (app.surf) — the open knowledge base
BioLegend
American biotechnology company
American biotechnology company
| Field | Value |
|---|---|
| name | BioLegend |
| type | Subsidiary |
| foundation | 2002 |
| location_city | San Diego, California |
| location_country | U.S. |
| area_served | Worldwide |
| key_people | Gene Lay, D.V.M., Founder and CEO |
| industry | Biotechnology |
| products | Antibodies, ELISA Kits and Sets, Recombinant Proteins, Custom Assay Development, Buffers and Solutions |
| parent | Revvity |
| homepage |
BioLegend is a global developer and manufacturer of antibodies and reagents used in biomedical research located in San Diego, California. It was incorporated in June 2002 and has since expanded to include BioLegend Japan KK, where it is partnered with Tomy Digital Biology Co., Ltd. in Tokyo, BioLegend Europe in the United Kingdom, BioLegend GmbH in Germany, and BioLegend UK Ltd in the United Kingdom. In July 2021, BioLegend was acquired by PerkinElmer for $5.25 billion and now operates as Revvity. BioLegend manufactures products in the areas of neuroscience, cell immunophenotyping, cytokines and chemokines, adhesion, cancer research, T regulatory cells, stem cells, innate immunity, cell-cycle analysis, apoptosis, and modification-specific antibodies. Reagents are created for use in flow cytometry, proteogenomics, ELISA, immunoprecipitation, Western blotting, immunofluorescence microscopy, immunohistochemistry, and in vitro or in vivo functional assays.
History
BioLegend was founded by CEO, Gene Lay, D.V.M., who was also the co-founder of PharMingen. In 2011, BioLegend co-developed and introduced Brilliant Violet(TM)-conjugated antibodies, using a novel fluorophore based on Nobel Prize-winning chemistry developed by Sirigen. In 2018, BioLegend introduced TotalSeq™ antibody-oligonucleotide conjugates for use in single cell proteogenomics analysis. BioLegend continued expansion and moved into a new 8-acre campus at BioLegend Way in 2019 with state of the art facilities designed to accommodate up to 1000 employees.
References
References
- "Antibodies and conjugates for biomedical research: News from Cambridge BioScience".
- (26 July 2021). "PerkinElmer to Acquire Antibody and Reagent Leader BioLegend". BioSpace.
- "PerkinElmer and BioLegend Announce Custom Immunoassay Development Collaboration for Drug Discovery Research".
- "BioLegend Company Profile".
This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.
Ask Mako anything about BioLegend — get instant answers, deeper analysis, and related topics.
Research with MakoFree with your Surf account
Create a free account to save articles, ask Mako questions, and organize your research.
Sign up freeThis content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.
Report